Akademik Veri Yönetim Sistemi
Turk Beyin Damar Hastaliklar Dergisi, cilt.9, sa.2, ss.67-70, 2003 (Scopus)
Different subjects require different aspirin dosages to achieve complete inhibition of platelet functions and the antiplatelet effect of a fixed dose aspirin is not constant over time in every patient. Some patients develop a progressively increasing dosage requirement, which is called "aspirin resistance". The debate still goes on for a similar effect of ticlopidine. The purpose of this study was to compare the effects of aspirin and ticlopidine on platelet functions over time. Ten patients (6 males, 4 females, ages between 42 and 79) with a history of minor stroke or transient ischemic attack were included in the study. Five patients were on aspirin and five were on ticlopidine treatment. Maximum intensity and 1 maximum rate of platelet aggregation (MIPA and MRPA) and ATP release (all with collagen and ADP) were evaluated before the initiation of aspirin or ticlopidine and during treatment on the 40th and 90th days. The platelet aggregation and ATP release values were found significantly reduced on the 40th day in both groups (p<0.01). The increase in MIPA and MRPA between the 40 th and 90th days was found significant in aspirin group (66.4%) than in the ticlopidine group (5.7%) (p<0.01). The results show that the resistance detected previously in patients on aspirin is not the case for patients on ticlopidine in the study period. Our data suggest that the antiaggregant efficacy of aspirin is not stable over time and may show decrease in a short period. We believe, therefore, periodical monitoring of platelet functions may be valuable in patients on aspirin prophylaxis and ticlopidine may be a good choise in patients, whose platelet aggregation tests cannot be evaluated properly.